Ecosystem Directory

Pioneering theranostics in immuno-oncology, PET radiotracer images T-cell & NK cell activation

A clinical-stage Australian biotech pioneering first-in-class radiopharmaceuticals for diagnostic and therapeutic use. They’re developing multiple theranostic agents targeting PD-L1, HER2, αvβ6 integrin, advanced prostate cancer, brain metastases, and more

A global medical technology leader offering advanced imaging systems (like PET/CT and PET/MR), molecular diagnostics, and integrated healthcare solutions. They offer Theranostic imaging tools & integrate dosimetry software (Hermia) into their platforms.

GMS operates 16 radiopharmacies in the Asia-Pacific region, compounding, dispensing, and distributing patient-specific radiopharmaceuticals—including potentially theranostic agents

Offers comprehensive oncology drug development services, including models and assays instrumental in theranostic research—supporting both diagnostics and therapeutics through their deep oncology expertise and global infrastructure

A global contract research organization (CRO) based in Ireland. Also launched integrated theranostic services in Australia.

A full‑service Contract Research Organization (CRO) with offices in the U.S & Australia.

A U.S.-based developer of precision quality control and calibration products for nuclear medicine, particularly SPECT and PET imaging, with worldwide distribution.

A Canadian CDMO that specializes in GMP manufacturing of radiopharmaceuticals—including isotopes like Lu-177, Ac-225, I-131, In-111, and Zr-89—enabling both diagnostic and therapeutic applications central to theranostic development.

Medidata is a leading provider of cloud-based SaaS and analytics platforms that support clinical research—from trial design and data capture to patient engagement, AI-powered insights, and decentralized trial technologies

MRP is a Hungarian CDMO specializing in radiopharmaceutical kits, cold kits, and nuclear medicine manufacturing, supplying imaging and potentially theranostic agents globally

Plus Therapeutics is a U.S. clinical-stage pharmaceutical company developing innovative targeted radiotherapeutics, particularly nanoliposome-encapsulated Rhenium‑186 (Re‑186)

A clinical-stage immuno-oncology imaging company that engineers “minibodies” (antibody fragments) for PET and optical imaging, enabling non-invasive visualization of immune cells (e.g. CD8 T‑cells) and tumor markers—a powerful theranostic tool for patient selection and treatment monitoring in cancer immunotherapy

A Swiss clinical‑stage biotech firm developing novel DARPin (Designed Ankyrin Repeat Protein) therapeutics for oncology. They’re advancing a Radio‑DARPin Therapy (RDT) platform—creating targeted radioligand treatments using DARPins to deliver radionuclide payloads

A leading global biopharmaceutical company developing medications and vaccines across oncology

A leading commercial supplier of Copper‑67 (Cu‑67), a high‑specific‑activity therapeutic isotope ideal for theranostic pairings when combined with diagnostic isotopes like Cu‑64 or Cu‑61—offering what’s called "perfect theranostic pairs" for precision imaging and therapy

A Tokyo-based biotech focused on peptide discovery (PDPS platform), developing peptide therapeutics and diagnostics—foundational to theranostic innovation.

International Centers for Precision Oncology (ICPO) Foundation is a non‑profit organization. It aims to advance Theranostics by scaling global patient access—through building a network of accredited clinical centers, standardized education & fostering a collaborative international community

A vertically integrated radiopharmaceutical biotech company focused on delivering diagnostic and therapeutic radionuclides, including leading supply of Lu‑177 and Ac‑225 isotopes.

IBA is a technology provider that helps develop and operate PET radiopharmaceutical production centers, and is a key supplier in radiopharma and theranostic infrastructure

a digital health radiology platform that connects patients, healthcare providers, and pharmaceutical partners to a network of U.S.-based, subspecialty radiologists—offering rapid, expert second‑opinion imaging reads/RECIST (e.g. CT, PET)

An Australian biotech developing dendrimer-based platforms for drug delivery and imaging agents, with potential theranostic applications, although it's primarily known for its antiviral and topical products.

Formed in 2021 as a sister company to Blue Earth Diagnostics—is focused on developing next‑generation targeted radiotherapeutics in oncology.

A Siemens Healthineers company, is the world’s largest PET radiopharmaceutical network—producing, distributing, and supporting PET tracers critical to the diagnostic side of theranostics, including agents used for patient selection and imaging guidance.

a technology provider in the field of nuclear medicine, specializing in the design, manufacture, and support of advanced radiopharmacy equipment such as synthesizers, dispensers, and quality-control systems for radiopharmaceutical production in research, clinical, and industrial settings

A radiopharmaceutical company focused on developing and delivering molecular diagnostics and therapeutics (theranostics). They manufacture and distribute PET imaging agents such as FDG, Pylarify (piflufolastat F-18), Neuraceq (florbetaben F-18), and others.

A global full-service Contract Research Organization (CRO) renowned for its reliable patient enrollment and on-time project delivery across diverse therapeutic areas including oncology

A clinical‑stage radiopharmaceutical company pioneering image‑guided alpha-particle targeted therapies (Pb‑212) paired with matching imaging tracers (Pb‑203), forming a true theranostic platform to both visualize and treat cancer

Conference Organizer

Focused on developing a new class of targeted radiopharmaceuticals for solid tumors, putting theranostic principles—pairing diagnostic specificity with therapeutic payload—at the core of their strategy

A leading radiopharmaceutical company known for products that help clinicians “Find, Fight, Follow” diseases, primarily through diagnostic imaging—and is expanding into radiotherapeutics and theranostics solutions

A commercial-stage biopharmaceutical company pioneering theranostic radiopharmaceuticals, developing both diagnostic and therapeutic agents for cancers and rare diseases—such as its FDA-approved PSMA‑PET imaging agent Illuccix®,CAIX for Renal Cell imaging and pipeline expansion into fibroblast activation protein (FAP) targeting for potential broad-spectrum theranostic utility

A German/U.S. MedTech that develops AI-driven software tools for enhanced prostate cancer management for personalized treatment prediction from PSMA PET

Swedish based, developer of vendor‑neutral molecular imaging and dosimetry software—most notably the Hermia platform—that supports PET/SPECT/CT/MR review, quantitative dosimetry (including voxel and organ dosimetry), and theranostics workflows 

Pioneering the manufacture and development of targeted alpha‑emitting radionuclide cancer therapies, aiming to bring advanced, high‑precision treatments to oncology patients globally

A subsidiary of Orano Med since 2011, specializes in macrocyclic chelating agents—highly engineered ligands that securely bind radioactive metals like lead‑212 for use in diagnostic imaging and Targeted Alpha Therapy (TAT) in oncology.

A global radiotherapeutics company with a comprehensive pipeline of radionuclide drug conjugates, such as the PSMA-targeted 225Ac‑FL‑020 and NTSR1-targeted 177Lu‑FL‑091, across Belgium, Germany, and China

A U.S.-based radiopharmaceutical CDMO offering services for both diagnostic and therapeutic radiopharmaceuticals—especially theranostic agents such as Gallium‑68 DOTATOC and novel radio‑ligand therapies. The company supports product development from research through commercialization

An Australian-based, global leader in automated PET radiochemistry instrumentation and radiopharmaceutical development, offering products like the MultiSyn, F‑18 FlexLab, and HPLC+ that power efficient tracer synthesis and quality control

Develops targeted alpha‑emitting radiotherapies, such as Actimab‑A (CD33-targeted using Ac‑225), and ATNM‑400, a prostate cancer-directed antibody radioconjugate—both deeply rooted in theranostics

A global leader in diagnostic imaging . It plays a pivotal role in diagnostic imaging agents that enable theranostic approaches. Bracco acquired Blue Earth in 2019.

A global contract research organization (CRO) formed by merger of Clinipace & dMed. Provides clinical trial development support and services

A Chiliean pharmaceutical company (founded 2010) develops radiopharmaceuticals for molecular imaging—like 18F, NaF, 68Ga‑PSMA, and 68Ga‑DOTATATE—commonly used for PET scans in oncology

A global medical technology company specializing in molecular imaging, radiopharmaceuticals imaging tools, AI-driven dosimetry systems and through strategic ownership of other companies.

A leader in clinical-stage radiopharmaceutical company pioneering Targeted Copper Theranostics (TCT) for both diagnostic imaging (64Cu) and therapeutic use (67Cu), powered by its proprietary SAR Technology platform

An Israeli clinical-stage biotech pioneering Smart Targeted Radioligands (STRs) for precision oncology—theranostic compounds that both image and treat cancer by pairing disease-specific peptide targeting with therapeutic (alpha or beta) radiation delivery.

The most advanced and leading radiopharmaceutical clinical trials network based in U.S. Enabling any participating community cancers to rapidly launch & conduct first-in-world Molecular Imaging & Therapeutic Radiopharmaceutical trials with unmatched efficiency, quality and accruals

A global, research-driven pharmaceutical company founded in 1941 and headquartered in Tokyo, Japan. It focuses on developing innovative prescription medicines, especially in oncology

A clinical-stage radiopharmaceutical biotech company engineering highly specific, peptide-based radiotherapies for cancer—exemplifying theranostics by combining tumor-targeted delivery with potent radionuclide payloads (e.g., Lu-177, Ac-225)

A leader in radiopharmaceuticals and nuclear medicine, offering a broad product portfolio supported by decades of experience and a presence in over 60 countries

A Canadian nuclear energy company that also generates medical isotopes (used in diagnostics and radioisotope therapies), making it a key upstream player in the theranostics ecosystem

A U.S.-based biotechnology company developing antibody-based theranostics, using its proprietary B-Body® bispecific (and now T-Body™ trispecific) platforms to engineer precision-targeted therapeutic antibodies for cancer

A leading global Contract Research Organization (CRO) that provides clinical research and regulatory consulting services to support biopharmaceutical and medical device companies in over 50 Countries

Develops precision-guided therapeutics, including biologics targeting challenging cancers; while not explicitly theranostic, their approach supports targeted therapeutic delivery

A global healthcare conglomerate active across pharmaceuticals, medical devices, and consumer health, with growing interest in radiopharmaceuticals and theranostics through various partnerships and research initiatives.

A global radiopharmaceutical company developing, manufacturing, and distributing diagnostic and therapeutic isotopes—particularly non-carrier-added Lu-177, Terbium-161, and Gallium-68 kits across Israel, Europe, and the U.S.

A China & U.S. based global CRO offering end-to-end clinical development services from Phase I to IV for pharmaceuticals, biologics, and medical devices

A global Contract Research Organization (CRO) based in the U.S, that provides comprehensive outsourced clinical development and data solutions across all drug development phases, serving pharmaceutical, biotechnology, and medical device clients.

a manufacturer of mobile and modular medical imaging units such as Mobile MRI, CT, PET/CT, and even transportable imaging trailers.

Life Couriers (formerly Associated Couriers) specializes in time-sensitive and compliant life science logistics across the U.S., including Theranostic agents, clinical trial materials, and precision medicine delivery.

A full‑service, global yet mid‑sized CRO with over 30 years of experience in conducting clinical research across multiple therapeutic areas including Oncology

A U.S.-based expert in nuclear medicine logistics, MDS provides safe, compliant door-to-door transport of radiopharmaceuticals nationwide, serving nuclear pharmacies and diagnostic/therapeutic radiopharma shipping clients.

A Swiss clinical-stage biotech company pioneering copper-based radiotheranostics, using Copper-61 for PET diagnostics and Copper-67 for targeted radiotherapy via its proprietary CuTrace™ platform, aiming to provide scalable, precise theranostic solutions across various cancers.

A U.S. based, oncology-focused CRO that helps advance cancer therapies from preclinical stages through clinical trials to FDA approval, offering trial design, data management, flow cytometry, and medical/regulatory support

Developing targeted alpha therapies using Lead-212 (²¹²Pb), aimed at selectively destroying cancer cells with minimal impact on healthy tissue, and has an active industrial production platform.

A Saudi Arabian radiopharmaceutical manufacturer that specializes in producing and supplying diagnostic and therapeutic radiopharmaceuticals, including cyclotron operation, radionuclide therapy, and radiopharmacy services

RayzeBio, based in San Diego, focuses on precision radiopharmaceutical therapies using actinium-225 (Ac‑225), an alpha-emitting isotope, positioning itself as a leader in the next wave of cancer theranostics.

Retrieving data. Wait a few seconds and try to cut or copy again.

develops vendor‑neutral medical imaging software used across radiation oncology, radiology, nuclear and molecular medicine, interventional radiology, and neuro/cardiac imaging—helping streamline complex clinical workflows and improve personalized patient care

A U.S./Swiss preclinical-stage biotech developing the YB‑800 theranostics platform, including radiopharmaceuticals and diagnostics targeting novel tumor markers

A Denmark‑based scientific Contract Research Organization (CRO) and Contract Development & Manufacturing Organization (CDMO) specializing in targeted radionuclide therapies, molecular imaging services, and translational research

Retrieving data. Wait a few seconds and try to cut or copy again.

A Swedish based global CRO that combines comprehensive clinical development services with flexible resourcing and Functional Service Provider solutions in Oncology and operates in more than 40 countries.

A precision oncology company leveraging next-generation antibody conjugation technologies & TRT to develop targeted cancer therapies

A clinical-stage oncology company pioneering targeted alpha therapeutics, using their proprietary Fast‑Clear™ linker technology to deliver alpha-emitting isotopes to tumors with improved safety and precision. In 2024 acquired by Astra Zeneca

A French CDMO offers turnkey technologies and supply chain solutions for the production and distribution of key theranostic radionuclides—including non-carrier-added Lutetium-177, Actinium-225, and Terbium-161

Australia's first publicly funded cancer center soley dedicated to cancer treatment, research and education.

Ratio Therapeutics (Boston) develops next‑generation small-molecule radiopharmaceuticals designed for theranostic use—able to accommodate both imaging and therapeutic radioisotopes—leveraging its Trillium™ targeting scaffold for precision oncology

ABX (Germany) manufactures and supports radiochemistry reagents, PET isotopes—such as precursors for nuclear medicine and radiopharmaceutical research—thus providing critical components for theranostic drug development

A innovative biotech incubator and umbrella company founded in 2018, specializing in next-generation radioligand therapies—particularly using Terbium-161—for prostate cancer and other tumor types as part of its theranostics portfolio

A global Contract Research Organization (CRO) owned by Thermo Fisher Scientific that provides comprehensive clinical trial and laboratory services to pharmaceutical, biotechnology, and medical device companies in 100+ Countries

A specialized conference series dedicated to advancing the development & clinical translation of targeted radiopharmaceuticals. With a strong focus on isotope supply chains, regulatory challenges, and innovative molecular design

A global contract research organization (CRO) based in the U.S. Provides oncology clinical trial services

Y‑mAbs is a commercial-stage biopharmaceutical company developing and commercializing novel radioimmunotherapies, centered around its Self‑Assembly DisAssembly Pre‑targeted Radioimmunotherapy (SADA‑PRIT) platform.

A global pharmaceutical leader that actively develops and commercializes radioligand therapies, exemplified by its acquisition Endocyte (Pluvicto®) and of Mariana Oncology to strengthen its theranostics pipeline

Engineers precision radiotherapeutics via its proprietary ROVEr™ platform, crafting antibody‑based agents with tunable pharmacokinetics to maximize tumor targeting while minimizing systemic toxicity—a strong theranostic approach

A Canadian specialized CDMO and leading developer of medical isotopes and radiopharmaceutical products—including Actinium-225, Lutetium-177, and Technetium-99m generators

A global pharmaceutical leader with extensive oncology and precision medicine pipelines and more recently involved with the development of Theranostic agents

A Belgian joint venture between IBA and SCK CEN focused on large-scale production of Actinium-225, a key alpha-emitting radioisotope used in theranostics for targeted cancer therapies—and has entered strategic agreements to supply Ac-225, such as with Bayer

A full‑service Contract Research Organization (CRO) with services in 40+ Countries

Eichrom supplies radiochemistry reagents and ion exchange resins extensively used in nuclear medicine and radiopharmaceutical research—crucial for theranostic development.

A molecular imaging company (a subsidiary of Bracco Imaging) that develops precision PET radiopharmaceuticals for cancer diagnostics, with a focus on agents like Axumin® and POSLUMA® for prostate cancer imaging using radiohybrid technology.

A global CDMO and radiopharmacy solutions provider dedicated to the full radiopharmaceutical lifecycle—from discovery and development through manufacturing, distribution, and commercialization of diagnostic imaging and therapeutic agents in support of theranostics. They operate an extensive network of facilities across the U.S., Canada, and Norway, and recently opened production/research sites in both New York’s Bronx and Cincinnati

Actithera has developed a platform that maximizes radiation dose to tumor through covalent bonding. It is isotope agnostic.

Ariceum Therapeutics GmbH develops next-generation targeted radiopharmaceuticals to visualize and treat cancer, clearly aligning with theranostic approaches

A venture capital and private equity firm that partners with founders to build and scale transformative companies across physical industries—ranging from manufacturing and energy to healthcare infrastructure, robotics, and supply chain systems .Eclipse co-created Nucleus RadioPharma, a CDMO centered on radiopharmaceutical development

Focuses on a Necrosis Targeting Platform Technology (NTPT) for cancer imaging and targeted radiotherapy—key theranostic components aiming to both detect and treat tumors

North America’s leading provider of waste collection, disposal, and recycling services, including hazardous waste management

An Austrian-based CDMO and analytical-services provider specializing in radiopharmaceutical development, production, and quality control—including the manufacture of therapeutic isotopes such as Lu‑177, Ac‑225, and F‑18

A Japanese company specializing in nuclear medicine imaging agents, actively involved in peptide-based theranostics and commercial-scale production of actinium‑225 for alpha therapies

Professional SocietyA non-profit scientific & professional organization that promotes the advancement of Nuclear Medicine, Molecular Imaging & Theranostics through education & research

A non‑profit, public‑benefit organization dedicated to advancing theranostics for cancer care on a global scales through aising awareness, educating patients and healthcare professionals, supporting research and development, and improving access to these targeted treatments worldwide

A U.S.-based manufacturer of radioactive materials—including the only FDA-approved Sodium Iodide I‑131 drug product produced domestically—alongside calibration standards, cobalt-60 sealed sources, and isotope APIs for third-party theranostics developers

A global pharma and life sciences company with a broad drug development portfolio in oncology with Radium 223 and including a growing pipeline of Theranostic Agents

Pharma (Japanese)

A clinical-stage biotech firm developing a novel class of alpha radioligand therapies (ARTs)—a clear theranostic modality—using Pb‑212 and their proprietary AlphaDirect™ technology to enable targeted delivery with high efficacy and safety

A clinical-stage biotech company developing next-generation targeted radiotherapies—notably radioantibody platforms that harness alpha-particle radiation for precision cancer treatment

SK Biopharmaceuticals a global biotech based in South Korea and is active in radiopharmaceutical therapy, partnerships with KIRAMS for actinium-225 RPT and with Full-Life for the FL-091 radioligand.

an Irish global CDMO delivering end-to-end pharmaceutical services—from drug discovery, development, and API production to clinical trial support and diagnostics—including biomarker-driven precision medicine solutions, which are pivotal to theranostic strategies

An oncology CRO specializing in preclinical and clinical testing—including radiopharmaceutical testing and patient-derived tumor models—supporting theranostic drug development through real-world validation platforms

A global leader in cyclotron technology & radiopharmaceutical manufacturing, supplying equipment

A leading philanthropic organization dedicated to funding & accelerating prostate cancer research

A France-based software company specializing in personalized voxel-based dosimetry tools for radiation oncology and nuclear medicine, including the PLANET® platform that supports multi-radionuclide dosimetry across diagnostic and therapeutic workflows

A global contract research organization (CRO) and functional service provider offering clinical development, resourcing, and quality services across multiple therapeutic areas, including oncology and diagnostics

a pioneering developer of high-definition, solid-state digital SPECT and SPECT/CT imaging systems—such as the ring-shaped VERITON-CT—that support theranostics applications by enabling precise imaging, dosimetry calculation, and treatment response monitoring using agents like Lu-177 PSMA

A full-service U.S.-based biopharmaceutical CDMO. Expertise in bioconjugation includes direct conjugation of Ac‑225 to monoclonal antibodies. They’ve also worked with other isotopes for theranostic applications, including Lu177, Zr‑89, In‑111, Bi‑213, Pb‑212

UPS Healthcare delivers end-to-end logistics and supply chain solutions tailored to pharmaceuticals, diagnostics, clinical trial logistics, and medical device delivery, making it suitable for theranostics and other sensitive healthcare shipments

A clinical-stage biotechnology company based in Houston, developing targeted radiopharmaceuticals and emphasizing a theranostic approach for cancer—supporting diagnosis, monitoring, and therapy with both alpha- and beta-labeled agents.

A global radiopharmaceutical CDMO based in Istanbul, supplying GMP-grade radioisotopes and theranostic radiopharmaceuticals—particularly high-specific-activity agents like Lutetium-177—across a robust logistics network serving over 70 countries.

A family-owned provider of medical imaging and therapeutic technologies, offering sales, service, consulting, education, and project management across modalities such as MRI, CT, ultrasound, nuclear/molecular imaging, and surgical systems

A U.S. based fully integrated biopharmaceutical solutions organization, providing both clinical research and commercial services to help bring therapies to market faster in 100+ Countries

Landauer specializes in radiation safety, offering dosimetry services, medical physics consulting, and radiation monitoring tools—technologies essential for safe handling of theranostic radiopharmaceuticals

FedEx Custom Critical®, a Nuclear Medicine shipping service, which is specifically designed for the transport of short-lived radiopharmaceuticals used in PET, SPECT, and therapeutic applications. This service provides time-definite delivery, chain-of-custody security, and regulatory compliance for radioactive medical shipments

A clinical biopharmaceutical company developing targeted radiotherapeutic agents using its proprietary Phospholipid Drug Conjugate (PDC™) platform, notably iopofosine (CLR‑131) and novel radioactive payloads for theranostic cancer treatments.

A biotech company developing personalized radiopharmaceuticals designed to diagnose and treat aggressive cancers, with a focus on precision theranostic modalities

A Novartis subsidiary, is developing next-generation precision radioligand therapies to deliver targeted radiation treatments with minimized impact on healthy tissue including the target B7H3.

A clinical-stage Belgian biotech developing precision radiopharmaceuticals using camelid single-domain antibodies. Their platform enables theranostic pairing—first imaging, then therapeutic dosing using the same targeting molecule

A clinical-stage radioligand therapy company developing next-gen radioligand treatments for cancer. It was acquired by Eli Lilly in October 2023 to bolster their oncology portfolio.

A healthcare investment firm (founded in 2015) that provides growth capital and strategic support to companies across the healthcare and life sciences sectors—including therapeutics, diagnostics, and related innovations

An early-stage radiopharmaceutical company developing novel oncology agents for solid tumors.

A major pharmaceutical company headquartered in Indianapolis, expanding into radiopharmaceuticals and theranostics notably through the $1.4 billion acquisition of Point Biopharma, which bolsters its radioligand therapy capabilities

Developing differentiated radiopharmaceutical therapies (RPTs) and companion diagnostics for hard-to-treat cancers, advancing theranostic agents such as ART‑101 (a PSMA-targeting radiotherapeutic) and a theranostic pair ARC‑706/ARC‑166

TheraSphere Y90

An immuno-oncology company developing radiotherapeutic and imaging agents targeting Glypican‑1 (GPC‑1) for solid tumors, with its lead candidate, Miltuximab®

A U.S.-based cyclotron and radiopharmaceutical technology company that provides compact cyclotron solutions and end-to-end manufacturing of diagnostics like therapeutic alpha radionuclides (Astatine-211, Actinium-225)

Brazilian Development & Distribution of RLT (works with Telix)

A Norwegian CDMO, established in 2023 as a spin-off from the Institute for Energy Technology and partially owned by Pharmalogic, that specializes in the development, commercial-scale production, and global distribution of radiopharmaceutical therapies.

MTTI is a that develops radiolabeled compounds that can be used in bother PET/SPECT imaging and Radionuclide therapy. It develops PSMA targeted ligands and their pipeline includes small molecules and antibody based radiopharmaceuticals.

A major multinational healthcare services and product distributor. It manages pharmaceutical and medical product supply, including operating a vast radiopharmacy network that supports diagnostic and therapeutic agents essential for theranostics workflow

A global, technology-enabled clinical research services provider formed from the merger of Calyx and Invicro. They deliver imaging biomarkers, eClinical solutions, clinical adjudication, and imaging core lab services with expertise in oncology

A clinical-stage oncology company developing novel targeted cancer therapies across platforms such as immunotherapies, radioligand therapies, and antibody-drug conjugates, using proprietary memory B cell hybridoma technology to uncover underexplored targets